Baird Capital Portfolio Company Zurex Pharma, Inc. Raises $9M Ahead of NDA Submission

Baird Capital Portfolio Company Zurex Pharma, Inc., a Wisconsin-based life sciences company with a novel antimicrobial technology program designed to minimize and prevent health care-associated infections, recently announced a significant capital raise of $9 million ahead of its first New Drug Application (NDA) submission.

Read Zurex Pharma’s full news release here for more information.